Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Thursday that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) for its chikungunya vaccine, CHIKV VLP.
This initiates the EMA's centralised review under accelerated assessment, potentially supporting approval of the vaccine by the European Commission in the first half of 2025.
The company also submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in June 2024, targeting a potential US approval in the same timeframe.
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
iOncologi acquires TargImmune Therapeutics
Akeso's Penpulimab receives Chinese regulatory approval
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Korro Bio receives FDA orphan drug designation for KRRO-110
BRAVO study confirms blue light cystoscopy reduces bladder cancer recurrence risk
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
Cantargia enrolls first patient in leukemia study with nadunolimab
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India
Centivax partners with Emery Pharma on universal flu vaccine
OsteoCentric Technologies partners with Globus Medical to expand innovative implant technology
Arvinas and Pfizer report positive Phase 3 results for vepdegestrant in breast cancer trial
PHI advances Next-Generation HoloMonitor CellSync for cell and gene therapy